VYNE Therapeutics Inc.VYNENASDAQ
Loading
Book Value/Share Growth Recovery in ProgressRecovering
Percentile Rank65
Year-over-Year Change
Year-over-year book value per share growth
Latest
-13.52%
↓ 3056% vs avg
Percentile
P65
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
0.46%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -13.52% |
| Q3 2025 | -17.45% |
| Q2 2025 | -12.07% |
| Q1 2025 | -15.44% |
| Q4 2024 | -18.02% |
| Q3 2024 | -15.14% |
| Q2 2024 | -10.21% |
| Q1 2024 | -31.49% |
| Q4 2023 | -18.53% |
| Q3 2023 | -33.59% |
| Q2 2023 | -34.85% |
| Q1 2023 | -22.44% |
| Q4 2022 | -16.05% |
| Q3 2022 | -17.14% |
| Q2 2022 | -17.03% |
| Q1 2022 | 10.74% |
| Q4 2021 | -19.72% |
| Q3 2021 | -22.31% |
| Q2 2021 | -23.37% |
| Q1 2021 | 147.78% |
| Q4 2020 | -35.03% |
| Q3 2020 | -42.78% |
| Q2 2020 | -68.46% |
| Q1 2020 | -42.57% |
| Q4 2019 | -21.57% |
| Q3 2019 | -15.07% |
| Q2 2019 | -13.88% |
| Q1 2019 | -11.77% |
| Q4 2018 | -11.96% |
| Q3 2018 | -7.57% |
| Q2 2018 | -26.61% |
| Q1 2018 | 440.29% |
| Q4 2017 | -25.80% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 100.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |